EDP Sciences logo
Subscriber Authentication Point
Search
Menu
All issues Volume 20 (2025) Math. Model. Nat. Phenom., 20 (2025) 29 References
Open Access
Issue
Math. Model. Nat. Phenom.
Volume 20, 2025
Article Number 29
Number of page(s) 19
DOI https://doi.org/10.1051/mmnp/2025029
Published online 07 January 2026
  1. M.-H. Chu, S.-W. Hsiao, Y.-C. Kao, H.-W. Yin, Y.-H. Kuo and C.-K. Lee, Cytotoxicity effect of constituents of Pinus taiwanensis Hayata Twigs on B16-F10 melanoma cells. Molecules 27 (2022) 2731. [Google Scholar]
  2. L. Sun, Z. Li, H. Shang and X. Xin, Hypericin enhances paclitaxel-induced B16-F10 cell apoptosis by activating a cytochrome c release—dependent pathway. Front. Pharmacol. 12 (2021) 652452. [Google Scholar]
  3. W.W. Overwijk and N.P. Restifo, B16 as a mouse model for human melanoma. Curr. Protoc. Immunol. 39 (2001) 20. [Google Scholar]
  4. P.A. Ott, S. Hu-Lieskovan, B. Chmielowski, R. Govindan, A. Naing, N. Bhardwaj, K. Margolin, M.M. Awad, M.D. Hellmann, J.J. Lin and T. Friedlander, A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183 (2020) 347-362. [Google Scholar]
  5. R.S. do Nascimento, M.K. Nagamine, G.F. De Toledo, L.M. Chaible, M.V. Tedardi, M.P. Del-Grande, I.I. daFonseca and M.L. Dagli, Sodium dichloroacetate attenuates the growth of B16-F10 melanoma in vitro and in vivo: an opportunity for drug repurposing. Anti-Cancer Drugs 32 (2021) 111-116. [Google Scholar]
  6. B.S. Gomes, J.D. Sousa and R.L. Mendes, Antimelanoma potential of natural compounds derived from plants: a systematic review of in vivo studies of B16 melanoma and its sublines. Braz. J. Med. Biol. Res. 58 (2025), https://doi.org/10.1590/1414-431X2025e14480. [Google Scholar]
  7. Z. Ya, Y. Hailemichael, W. Overwijk and N.P. Restifo, Mouse model for pre-clinical study of human cancer immunotherapy. Curr. Protoc. Immunol. 108 (2015) 20.1.1-20.1.43. [Google Scholar]
  8. N. Cogno, C. Axenie, R. Bauer and V. Vavourakis, Agent-based modeling in cancer biomedicine: applications and tools for calibration and validation. Cancer Biol. Ther. 25 (2024) 2344600. [Google Scholar]
  9. R. Anguelov, G. Manjunath, A.E. Phiri, T.T. Nyakudya, P. Bipath, J.C. Serem and Y.N. Hlophe, Quantifying assays: inhibition of signalling pathways of cancer. Math. Med. Biol. 40 (2023) 266-290. [Google Scholar]
  10. C. Basson, A. E. Phiri, G. Manjunath, R. Anguelov, J.C. Serem, P. Bipath and Y.N. Hlophe, In vitro effects and mathematical modelling of CTCE-9908 (a chemokine receptor 4 antagonist) on melanoma cell survival. Clin. Exp. Pharmacol. Physiol. 51 (2024) e13865. [Google Scholar]
  11. V. Kirkin, W. Thiele, P. Baumann, R. Mazitschek, K. Rohde, G. Fellbrich, W. Herbert, J. Waltenberger, A. Giannis and J.P. Sleeman, MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo. Int. J. Cancer 112 (2004) 986-993. [Google Scholar]
  12. Y.N. Hlophe and A.M. Joubert, Vascular endothelial growth factor-C on the upregulation of chemokine receptor-4 and vascular endothelial growth factor receptor-3 on melanoma and endothelioma adhesion. J. Cell. Mol. Med. 26 (2022) 5743-5754. [Google Scholar]
  13. R.B. Issaka, S. Oommen, S.K. Gupta, G. Liu, J.L. Myers, J.H. Ryu and N.E. Vlahakis, Vascular endothelial growth factors C and D induces proliferation of lymphangioleiomyomatosis cells through autocrine crosstalk with endothelium. Am. J. Pathol. 175 (2009) 1410-1420. [Google Scholar]
  14. K. Letsoalo, C. Basson, T. Nyakudya and Y. Hlophe, Exploring phytochemical adjuvant therapy in melanoma treatment: The effects of MAZ-51 and zingerone on melanoma cell proliferation. Clin. Exp. Pharmacol. Physiol. (In press). [Google Scholar]
  15. K. Letsoalo, E. Nortje, S. Patrick, T. Nyakudya and Y. Hlophe, Decoding the synergistic potential of MAZ-51 and zingerone as therapy for melanoma treatment in alignment with the sustainable development goals. Cell. Biochem. Funct. 42 (2024) e3950. [Google Scholar]
  16. A.M. Jarrett, E.A.B.F. Lima, D.A. Hormuth, II, M.T. McKenna, X. Feng, D.A. Ekrut, A.C.N. Resende, A. Brock and T.E. Yankeelov, Mathematical models of tumor cell proliferation: a review of the literature. Expert Rev. Anticancer Ther. 18 (2018) 1271-1286. [Google Scholar]
  17. A. Yin, D.J.A.R. Moes, J.G.C. van Hasselt, J.J. Swen and H.-J. Guchelaar, A review of mathematical models for tumor dynamics and treatment resistance evolution of solid tumors. CPT Pharmacom. Syst. Pharmacol. 8 (2019) 720-737. [Google Scholar]
  18. M. Kohandel, S. Sivaloganathan and A. Oza, Mathematical modeling of ovarian cancer treatments: sequencing of surgery and chemotherapy. J. Theoret. Biol. 242 (2006) 62-68. [Google Scholar]
  19. H.E. Skipper, F.M. Schabel Jr. and W.S. Wilcox, Experimental evaluation of potential anticancer agents XIII: on the criteria and kinetics associated with curability of experimental leukemia. Cancer Chemother. Rep. 35 (1964) 1-111. [Google Scholar]
  20. J.C. Panetta, A mathematical model of breast and ovarian cancer treated with paclitaxel. Math. Biosci. 146 (1997) 89-113. [Google Scholar]
  21. K. Renner-Martin, N. Brunner, M. Kuhleitner, W.G. Nowak and K. Scheicher, On the exponent in the Von Bertalanffy growth model. PeerJ 6 (2018) e4205. [Google Scholar]
  22. R.I. Fletcher, A general solution for the complete Richards function. Math. Biosci. 27 (1975) 349-360. [Google Scholar]
  23. S.M. Markov, The Gompertz model revisited and modified using reaction networks: mathematical analysis. Biomath 10 (2021) 2110023. [Google Scholar]
  24. J. West, Z. Hasnain, P. Macklin and P.K. Newton, An evolutionary model of tumor cell kinetics and the emergence of molecular heterogeneity driving gompertzian growth. SIAM Rev. 58 (2016) 716-736. [Google Scholar]
  25. F.J. Richards, A flexible growth function for empirical use. J. Exp. Bot. 10 (1959) 290-300. [Google Scholar]
  26. A. Calaprice, The Ultimate Quotable Einstein, Princeton University Press, Princeton and Oxford (2011). https://press.princeton.edu/books/hardcover/9780691138176/the-ultimate-quotable-einstein. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.